AVTE

Aerovate Therapeutics (AVTE)

About Aerovate Therapeutics (AVTE)

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Details

Daily high

$2.14

Daily low

$1.98

Price at open

$2.02

52 Week High

$32.42

52 Week Low

$1.25

Market cap

61.5M

Dividend yield

0.00%

Volume

100

Avg. volume

232,436

P/E ratio

-.68

Aerovate Therapeutics News